Dyadic International, Inc., a global biotechnology company, has announced a proposed public offering of its common stock. The offering will be managed by Craig-Hallum Capital Group LLC, serving as the sole managing underwriter. Although the specifics of the offering, such as its size and terms, are still subject to market conditions, the company plans to utilize the net proceeds for working capital and general corporate purposes, including product development, sales, and marketing. The securities will be offered under an effective shelf registration statement filed with the SEC. Further details will be available in a final prospectus supplement to be filed with the SEC.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.